Overexpression of TSG101 causes cellular plasticity and development of adenosquamous mammary carcinoma

The mammalian Tumor Susceptibility Gene 101 (TSG101) encodes a protein with diverse functions that control the proliferation and survival of cells, but its role in malignant transformation has remained enigmatic. To study the pro-tumorigenic functions of TSG101, we developed a transgenic mouse model that expresses exogenous TSG101 along with a luciferase reporter in a ligand-controlled manner in the mammary gland epithelium. Females overexpressing TSG101 develop ductal hyperplasia, adenomyoepitheliomas, and palpable adenosquamous carcinomas at an average latency of aproximately 10 months. These metaplastic mammary tumors are comprised of transforming basal and luminal epithelial cells, and using a GFP reporter strain to monitor the transgene activation on the single-cell level, we determined that the epithelial heterogeneity within transforming ducts and carcinomas was the result of cellular plasticity wihtin the luminal epithelium. On the molecular level, TSG101-induced mammary tumors are triple-negative and exhibit gene expression signatures of Wnt and inflammatory cytokine signaling, which are key regulators of epithelial cell fate. The ligand-controlled downregulation of exogenous TSG101 in established carcinomas led to tumor regression. We demonstrated that the TSG101-mediated activation of PI3K/AKT signaling as well as upregulation of Cyclin D1 and MDM2 are dependent on the perpetual expression of the oncoprotein. The collective findings of this study provide in vivo evidence that TSG101 has pro-tumorigenic properties that extend to cancer progression and maintenance, suggesting that this protein could be a rational molecular target to prevent and treat a subset of mammary tumors.